Synexus is the world's largest multi-national company focused on the recruitment and running of clinical trials.
Headquartered in Manchester, UK, Synexus is one of the only global patient enrolment and investigator site management organisations (SMO). It enrols and manages patients for large, complex clinical trials on behalf of a number of leading international pharmaceutical, biotechnology and contract research organisations.
The business employs more than 850 people and operates via an international network of 92 dedicated research centres, 25 of which are owned by Synexus. This enables the business to access more than 79 million potential patients worldwide on behalf of its customers.
In February 2015 LDC completed a £83million secondary buyout of Synexus. LDC backed the management team to realise a clear strategy for organic growth and a targeted buy and build to further enhance the customer offering and its geographic footprint.
In June 2016, LDC completed the exit of Synexus in a deal that values the business at £178million. Synexus has been acquired by Jaguar Holding Company Luxembourg SARL and the transaction generates a 2.3x money multiple for LDC.
During LDCs tenure the business completed the acquisition of Research Across America (RAA). The deal, which completed in March 2016, enabled Synexus to enter the US market, as well as providing additional expertise in areas such as dermatology and genetics. LDC’s investment also supported the organic growth of the business and in the last 12 months, Synexus opened new dedicated research centres in Bulgaria, Poland and Romania, strengthening its market-leading position in Europe.
The financial backing of LDC has enabled us to drive growth across the US and Europe, putting the business in an extremely strong position as one of the only global SMOs, and the team has also provided invaluable strategic support. The pharma industry is looking to bring new drugs to market as quickly and cost-effectively as possible, and this is where Synexus can help. Our time working with LDC has created a strong platform to build on moving forward. As the company enters the next phase, we the management team are excited and look forward to continuing to grow the company and bring life changing therapies for patients worldwide.